Innovative Treatment Approaches to Orphan CNS Developmental Disorders
Hosted by Jason Butler, Senior Research Analyst
Wednesday, June 19, 10:00 a.m.
Marinus Pharmaceuticals, Inc. (MRNS) Scott Braunstein, Executive Chairman
Newron Pharmaceuticals SPA (SWX:NWRN) Stefan Weber, Chief Executive Officer
Ovid Therapeutics Inc. (OVID) Dr. Amit Rakhit, CMO, Head of Research & Development
A discussion of novel pharmacological approaches to treating orphan genetic disorders that primarily impact the central nervous system, such as CDKL5-deficiency, Angelman syndrome, and Rett syndrome, to name a few. Each participating company has small molecule drug-candidates in early- to late-stage development that target signaling pathways in the brain to treat one or more of these conditions.
Drug Pricing: Past, Present and Future
Hosted by Don Ellis, Senior Research Analyst
Thursday, June 20, 9:00 a.m.
DAS Health Partners, LLC David Schlett, President
A conversation about the ways in which drug pricing has been affected by PBM and retail pharmacy consolidation and what to expect in the future. Relationships between PBMs, health insurers, manufacturers, commercial payers, and CMS reimbursement continue to shift. As a consequence, how do PBMs affect manufacturers’ WAC/ASP and impact the cost of drug therapy? There is now political awareness that PBMs, which initially evolved to reduce drug pricing, may currently adversely affect WAC/ASPs via rebating and charge-back strategies. The discussion will investigate whether the operating profit that manufacturers previously dedicated to discovering new drugs and improving patient lives is now shifting to middlemen like PBMs and/or supporting high margins for MCOs and health plans.
Hosted by David Turkaly, Senior Research Analyst
Thursday, June 20, 11:00 a.m.
electroCore, Inc. (ECOR) Frank Amato, Chief Executive Officer
Pulse Biosciences, Inc. (PLSE) Edward Ebbers, EVP & GM, Dermatology
A new, device-based wave of innovation known as bioelectronic medicine (BEM) continues to demonstrate potential to drive a sea change in the treatment of a broad range of medical conditions. electroCore and Pulse Biosciences are two early-stage public companies that fall under the BEM umbrella, with novel technologies focusing on disease state targeting without the systemic effects of pharmaceuticals.
Medicines and Gene Therapy for Rare Disease: In Search of a Sustainable Pricing Model
Hosted by Liisa Bayko, Senior Research Analyst
Thursday, June 20, 12:00 p.m.
Harvard Pilgrim Health Care, Inc. Dr. Michael Sherman, Chief Medical Officer
The explosion of medicines approved to treat rare disease over the past decade and recent advances in gene therapy are putting the current U.S. drug pricing paradigm to the test. The U.S. healthcare system, built on a fee-for-service model but shifting to a value-based payment model, was not designed to handle high-cost, one-shot therapies like gene therapy. Given the hefty price for these therapies, payers have raised questions about whether gene therapy is too expensive relative to its perceived clinical benefits. Are the high prices for these medicines sustainable? In this session we will dive into the real-world challenges of establishing pricing and value for rare disease medicines and gene therapy and will provide insight into where the field is headed.
Trends in Life Sciences Venture Capital
Hosted by JMP Securities Investment Banking
Thursday, June 20, 1:00 p.m.
1315 Capital Matthew Reber, Partner
Acorn Bioventures Anders Hove, Portfolio Manager
Novo Ventures Karen Hong, Partner
As the life sciences sector continually evolves, so must the investment professionals who fund innovation. The panelists will discuss the areas of greatest interest to them in today’s marketplace and will share their perspectives on the investment approaches that do and do not work in the highly specialized healthcare industry.